Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models

Investigational New Drugs

Volumn 14, Issue 3, 1996, Pages 243-247

  Merriman, R L ^a   Hertel, L W ^a   Schultz, R M ^a   Houghton, P J ^b   Houghton, J A ^b   Rutherford, P G ^a   Tanzer, L R ^a   Boder, G B ^a   Grindey, G B ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antitumor activity; Cytosine arabinoside; Gemcitabine; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LUNG CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLONIC NEOPLASMS; CYTARABINE; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 0029802507     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00194526     Document Type: Article

References (20)

1. Hertel LW, Kroin JS, Misnr JW, Tustin JM: Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406-2409, 1988
2. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ: Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248:2481-2486, 1982
3. Chabner BA, Meyers CE: Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. J.B. Lippincott, Philadelphia, pp 167, 1982
4. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine. Cancer Res 50:4417-4422, 1990
5. Braakhuis BJM, van Dongen GAMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211-214, 1991
6. Boven E, Schipper H, Erkelens CAM: The influence of the schedule and the dose of gemcitabine on the antitumor efficacy in experimental human cancer. Br J Cancer 68:52-56, 1993
7. Peters GJ, Schornagel JH, Milano GA: Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17:123-156, 1993
8. Lund B, Kristjansen PEG, Hansen HH: Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993
9. Houghton JA, Taylor DM: Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 37:213-223, 1978
10. Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB: Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5:223-228, 1993
11. Worzalla JF, Bewley JR, Grindey GB: Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs 8:241-251, 1990
12. Bovin E, Winograd B: The Nude Mouse in Oncology Research. CRC Press, Boca Ratan, Fl, p 135, 1991
13. Wils JA: Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res 9:1027-1032, 1989
14. Chang BK: Differential sensitivity of pancreatic adenocarcinoma cell lines to chemotherapeutic agents in culture. Cancer Treat Rep 57:355-361, 1983
15. Chang BK, Fredericks W, Rustum YM, Baker RM: Levels of P-glycoprotein in pancreatic cancer cells lines: relation to inherent drug resistance. Proc Am Soc Clin Oncol 7:115(abstr), 1988
16. Huang P, Chubb S, Hertel LW et al.: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6100-6117, 1991
17. Heinemann V, Xu Y-Z, Chubb S et al.: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572, 1990
18. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988
19. Plunkett W, Grindey GB: Pharmacokinetics of the 5′-triphosphates of arabinosylcytosine and 2′,2′-difluorodeoxycytidine in L1210 cells. Nucleic Acids Symp Ser 18:77-79, 1987
20. Fujita M, Fujita F, Inaba H, Taguchi T: Antitumor activity of LY188011, a new deoxydytidine analog, against human cancers xenografted into nude mice. Jpn J Cancer Chemother 21:517-523, 1994